Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Regenxbio Inc RGNX

Healthcare Biotechnology
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.


NDAQ:RGNX - Post by User

Regenxbio Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Post by AviseAnalyticson Aug 10, 2021 8:55am
87 Views
Post# 33677354

RegenxBio Inc: A Compelling Investment Opportunity!

RegenxBio Inc: A Compelling Investment Opportunity!

Excited to share an article on RegenxBio, Inc (NASDAQ: RGNX), a leader in gene therapy , whose NAV technology platform is behind Zolgensma, Novartis's drug intended for the treatment of Spinal Muscular Dystrophy.

Multiple Strategic Collaboration with industry leading pharmaceutical companies, a robust patent portfolio, a very promising pipeline and experienced management team make this company a must watch in our list!

Read on to find out more!

[url=https://www.aviseanalytics.com/regenxbio-inc-a-compelling-investment-opportunity/]Learn More[/url]

https://www.aviseanalytics.com/regenxbio-inc-a-compelling-investment-opportunity/

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities